Molecular chess? Hallmarks of anti-cancer drug resistance

The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years. Resistance to anti-cancer drugs can...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cancer 2017-01, Vol.17 (1), p.10-10, Article 10
Hauptverfasser: Cree, Ian A, Charlton, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10
container_issue 1
container_start_page 10
container_title BMC cancer
container_volume 17
creator Cree, Ian A
Charlton, Peter
description The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years. Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug targets, (2) expression of drug pumps, (3) expression of detoxification mechanisms, (4) reduced susceptibility to apoptosis, (5) increased ability to repair DNA damage, and (6) altered proliferation. It is clear, however, that changes in stroma and tumour microenvironment, and local immunity can also contribute to the development of resistance. Cancer cells can and do use several of these mechanisms at one time, and there is considerable heterogeneity between tumours, necessitating an individualised approach to cancer treatment. As tumours are heterogeneous, positive selection of a drug-resistant population could help drive resistance, although acquired resistance cannot simply be viewed as overgrowth of a resistant cancer cell population. The development of such resistance mechanisms can be predicted from pre-existing genomic and proteomic profiles, and there are increasingly sophisticated methods to measure and then tackle these mechanisms in patients. The oncologist is now required to be at least one step ahead of the cancer, a process that can be likened to 'molecular chess'. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients, it is becoming clear that personalised strategies are required to obtain best results.
doi_str_mv 10.1186/s12885-016-2999-1
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5214767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A480559120</galeid><sourcerecordid>A480559120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-2279a5bcf723cca98eaed7816a568f393cbaf165d0050d61581f174715beab9a3</originalsourceid><addsrcrecordid>eNptkk9v1DAQxSMEoqXwAbigSEioHFI8ydqxL6CqAlqpCIk_Z2vijHddvHFrJ6h8exxtKRuEfLA1_s3z-OkVxXNgJwBSvElQS8krBqKqlVIVPCgOYdVCVa9Y-3DvfFA8SemKMWglk4-Lg1oyLiRXh4X6FDyZyWMszYZSeleeo_dbjD9SGWyJw-gqg4OhWPZxWpeRkkvjXHhaPLLoEz2724-K7x_efzs7ry4_f7w4O72sjGDtWNV1q5B3xrZ1YwwqSUh9K0FgnsA2qjEdWhC8Z4yzXgCXYKHNg_OOsFPYHBVvd7rXU7el3tAwRvT6Oro85S8d0OnlzeA2eh1-al7n_4s2CxzfCcRwM1Ea9dYlQ97jQGFKGiQXXHEmmoy-_Ae9ClMc8vcyJZpsNm_YX2qNnrQbbMjvmllUn66ys1xBPVMn_6Hy6mnrTBjIulxfNLxeNGRmpNtxjVNK-uLrlyX7ao_dEPpxk4KfRheGtARhB5oYUopk740DpucQ6V2IdA6RnkOkIfe82Hf8vuNPaprfSHS-oA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1863885530</pqid></control><display><type>article</type><title>Molecular chess? Hallmarks of anti-cancer drug resistance</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cree, Ian A ; Charlton, Peter</creator><creatorcontrib>Cree, Ian A ; Charlton, Peter</creatorcontrib><description>The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years. Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug targets, (2) expression of drug pumps, (3) expression of detoxification mechanisms, (4) reduced susceptibility to apoptosis, (5) increased ability to repair DNA damage, and (6) altered proliferation. It is clear, however, that changes in stroma and tumour microenvironment, and local immunity can also contribute to the development of resistance. Cancer cells can and do use several of these mechanisms at one time, and there is considerable heterogeneity between tumours, necessitating an individualised approach to cancer treatment. As tumours are heterogeneous, positive selection of a drug-resistant population could help drive resistance, although acquired resistance cannot simply be viewed as overgrowth of a resistant cancer cell population. The development of such resistance mechanisms can be predicted from pre-existing genomic and proteomic profiles, and there are increasingly sophisticated methods to measure and then tackle these mechanisms in patients. The oncologist is now required to be at least one step ahead of the cancer, a process that can be likened to 'molecular chess'. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients, it is becoming clear that personalised strategies are required to obtain best results.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-016-2999-1</identifier><identifier>PMID: 28056859</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Cancer treatment ; Care and treatment ; Chemotherapy ; Drug resistance ; Drug Resistance, Neoplasm - physiology ; Health aspects ; Humans ; Kinases ; Medical Oncology - trends ; Mutation ; Neoplasms - drug therapy ; Neoplasms - pathology ; Pharmaceutical industry ; Precision Medicine - trends ; Review</subject><ispartof>BMC cancer, 2017-01, Vol.17 (1), p.10-10, Article 10</ispartof><rights>COPYRIGHT 2017 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2017</rights><rights>The Author(s). 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-2279a5bcf723cca98eaed7816a568f393cbaf165d0050d61581f174715beab9a3</citedby><cites>FETCH-LOGICAL-c607t-2279a5bcf723cca98eaed7816a568f393cbaf165d0050d61581f174715beab9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214767/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214767/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28056859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cree, Ian A</creatorcontrib><creatorcontrib>Charlton, Peter</creatorcontrib><title>Molecular chess? Hallmarks of anti-cancer drug resistance</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years. Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug targets, (2) expression of drug pumps, (3) expression of detoxification mechanisms, (4) reduced susceptibility to apoptosis, (5) increased ability to repair DNA damage, and (6) altered proliferation. It is clear, however, that changes in stroma and tumour microenvironment, and local immunity can also contribute to the development of resistance. Cancer cells can and do use several of these mechanisms at one time, and there is considerable heterogeneity between tumours, necessitating an individualised approach to cancer treatment. As tumours are heterogeneous, positive selection of a drug-resistant population could help drive resistance, although acquired resistance cannot simply be viewed as overgrowth of a resistant cancer cell population. The development of such resistance mechanisms can be predicted from pre-existing genomic and proteomic profiles, and there are increasingly sophisticated methods to measure and then tackle these mechanisms in patients. The oncologist is now required to be at least one step ahead of the cancer, a process that can be likened to 'molecular chess'. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients, it is becoming clear that personalised strategies are required to obtain best results.</description><subject>Cancer treatment</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - physiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Kinases</subject><subject>Medical Oncology - trends</subject><subject>Mutation</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Pharmaceutical industry</subject><subject>Precision Medicine - trends</subject><subject>Review</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkk9v1DAQxSMEoqXwAbigSEioHFI8ydqxL6CqAlqpCIk_Z2vijHddvHFrJ6h8exxtKRuEfLA1_s3z-OkVxXNgJwBSvElQS8krBqKqlVIVPCgOYdVCVa9Y-3DvfFA8SemKMWglk4-Lg1oyLiRXh4X6FDyZyWMszYZSeleeo_dbjD9SGWyJw-gqg4OhWPZxWpeRkkvjXHhaPLLoEz2724-K7x_efzs7ry4_f7w4O72sjGDtWNV1q5B3xrZ1YwwqSUh9K0FgnsA2qjEdWhC8Z4yzXgCXYKHNg_OOsFPYHBVvd7rXU7el3tAwRvT6Oro85S8d0OnlzeA2eh1-al7n_4s2CxzfCcRwM1Ea9dYlQ97jQGFKGiQXXHEmmoy-_Ae9ClMc8vcyJZpsNm_YX2qNnrQbbMjvmllUn66ys1xBPVMn_6Hy6mnrTBjIulxfNLxeNGRmpNtxjVNK-uLrlyX7ao_dEPpxk4KfRheGtARhB5oYUopk740DpucQ6V2IdA6RnkOkIfe82Hf8vuNPaprfSHS-oA</recordid><startdate>20170105</startdate><enddate>20170105</enddate><creator>Cree, Ian A</creator><creator>Charlton, Peter</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170105</creationdate><title>Molecular chess? Hallmarks of anti-cancer drug resistance</title><author>Cree, Ian A ; Charlton, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-2279a5bcf723cca98eaed7816a568f393cbaf165d0050d61581f174715beab9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cancer treatment</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - physiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Kinases</topic><topic>Medical Oncology - trends</topic><topic>Mutation</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Pharmaceutical industry</topic><topic>Precision Medicine - trends</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cree, Ian A</creatorcontrib><creatorcontrib>Charlton, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cree, Ian A</au><au>Charlton, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular chess? Hallmarks of anti-cancer drug resistance</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2017-01-05</date><risdate>2017</risdate><volume>17</volume><issue>1</issue><spage>10</spage><epage>10</epage><pages>10-10</pages><artnum>10</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years. Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug targets, (2) expression of drug pumps, (3) expression of detoxification mechanisms, (4) reduced susceptibility to apoptosis, (5) increased ability to repair DNA damage, and (6) altered proliferation. It is clear, however, that changes in stroma and tumour microenvironment, and local immunity can also contribute to the development of resistance. Cancer cells can and do use several of these mechanisms at one time, and there is considerable heterogeneity between tumours, necessitating an individualised approach to cancer treatment. As tumours are heterogeneous, positive selection of a drug-resistant population could help drive resistance, although acquired resistance cannot simply be viewed as overgrowth of a resistant cancer cell population. The development of such resistance mechanisms can be predicted from pre-existing genomic and proteomic profiles, and there are increasingly sophisticated methods to measure and then tackle these mechanisms in patients. The oncologist is now required to be at least one step ahead of the cancer, a process that can be likened to 'molecular chess'. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients, it is becoming clear that personalised strategies are required to obtain best results.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>28056859</pmid><doi>10.1186/s12885-016-2999-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2017-01, Vol.17 (1), p.10-10, Article 10
issn 1471-2407
1471-2407
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5214767
source MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Cancer treatment
Care and treatment
Chemotherapy
Drug resistance
Drug Resistance, Neoplasm - physiology
Health aspects
Humans
Kinases
Medical Oncology - trends
Mutation
Neoplasms - drug therapy
Neoplasms - pathology
Pharmaceutical industry
Precision Medicine - trends
Review
title Molecular chess? Hallmarks of anti-cancer drug resistance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A20%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20chess?%20Hallmarks%20of%20anti-cancer%20drug%20resistance&rft.jtitle=BMC%20cancer&rft.au=Cree,%20Ian%20A&rft.date=2017-01-05&rft.volume=17&rft.issue=1&rft.spage=10&rft.epage=10&rft.pages=10-10&rft.artnum=10&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-016-2999-1&rft_dat=%3Cgale_pubme%3EA480559120%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1863885530&rft_id=info:pmid/28056859&rft_galeid=A480559120&rfr_iscdi=true